Cargando…

Patients With Autoimmune Thyroiditis Present Similar Immunological Response to COVID-19 BNT162b2 mRNA Vaccine With Healthy Subjects, While Vaccination May Affect Thyroid Function: A Clinical Study

BACKGROUND: This is the first study, that aimed: a) to compare immune response, namely the kinetics of neutralizing antibodies (Nabs), after vaccination with BNT162b2 mRNA vaccine (Comirnaty, Pfizer/BioNTech) between patients with autoimmune thyroiditis and controls, and b) to investigate changes in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paschou, Stavroula A., Karalis, Vangelis, Psaltopoulou, Theodora, Vasileiou, Vasiliki, Charitaki, Ioanna, Bagratuni, Tina, Ktena, Vassiliki, Papandroulaki, Fotini, Gumeni, Sentiljana, Kassi, Georgia N., Trougakos, Ioannis P., Terpos, Evangelos, Dimopoulos, Meletios A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902239/ https://www.ncbi.nlm.nih.gov/pubmed/35273575 http://dx.doi.org/10.3389/fendo.2022.840668

Ejemplares similares

COVID-19 BNT162b2 mRNA vaccine for patients with type 2 diabetes mellitus
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Patients with type 2 diabetes mellitus present similar immunological response to COVID-19 BNT162b2 mRNA vaccine to healthy subjects: a prospective cohort study
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals
por: Terpos, Evangelos, et al.
Publicado: (2021)

Recurring subacute thyroiditis after SARS-CoV-2 mRNA vaccine: A case report
por: Vasileiou, Vasiliki, et al.
Publicado: (2021)

Kinetics of Anti-Sars-Cov-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers
por: Terpos, Evangelos, et al.
Publicado: (2021)

Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers
por: Terpos, Evangelos, et al.
Publicado: (2021)

Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients
por: Trougakos, Ioannis P., et al.
Publicado: (2021)

Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals
por: Terpos, Evangelos, et al.
Publicado: (2021)

Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy Individuals
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients
por: Bergamaschi, Cristina, et al.
Publicado: (2021)

Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222
por: Terpos, Evangelos, et al.
Publicado: (2022)

Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Patients with Multiple Myeloma and Prior COVID-19 Have Superior Antibody Responses Against Sars-Cov-2 Compared with Fully Vaccinated Myeloma Patients with the BNT162b2 Vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis
por: Papadopoulos, Dimitris, et al.
Publicado: (2022)

Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy
por: Terpos, Evangelos, et al.
Publicado: (2022)

Early and late endocrine complications of COVID-19
por: Kazakou, Paraskevi, et al.
Publicado: (2021)

Antibody Response after Vaccination for Sars-Cov-2 in Patients with AL Amyloidosis and the Impact of Therapy
por: Kastritis, Efstathios, et al.
Publicado: (2021)

High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events
por: Terpos, Evangelos, et al.
Publicado: (2021)

Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Prospective Assessment of Biomarkers of Hypercoagulability in Oncological Patients and Healthcare Workers Following Vaccination Against Sars-Cov-2 with the mRNA Vaccine. the Roadmap-COVID-19-Vaccin Study
por: Van Dreden, Patrick, et al.
Publicado: (2021)

Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients
por: Liontos, Michalis, et al.
Publicado: (2021)

Hyponatraemia in patients on immune checkpoint inhibitors
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis
por: Kastritis, Efstathios, et al.
Publicado: (2021)

Cross Talk of Proteostasis and Mitostasis in Cellular Homeodynamics, Ageing, and Disease
por: Gumeni, Sentiljana, et al.
Publicado: (2016)

The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
por: Terpos, Evangelos, et al.
Publicado: (2021)

Longitudinal Analysis of Antibody Response Following SARS-CoV-2 Infection Depending on Disease Severity: A Prospective Cohort Study
por: Zirou, Christina, et al.
Publicado: (2023)

P-127: Patients with Multiple Myeloma on treatment with Anti-CD38 or Anti-BCMA agents have a suboptimal humoral response following COVID-19 vaccination
por: Terpos, Evangelos, et al.
Publicado: (2021)

Autophagy activation can partially rescue proteasome dysfunction‐mediated cardiac toxicity
por: Papanagnou, Eleni‐Dimitra, et al.
Publicado: (2022)

Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose
por: Terpos, Evangelos, et al.
Publicado: (2021)

Gender differences in COVID-19
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Patients with Multiple Myeloma on Anti-CD38 or Anti-BCMA Based Regimens and Patients with Waldenstrom's Macroglobulinemia Under Rituximab or BTK Inhibitors Have a Poor Humoral Response Following COVID-19 Vaccination
por: Terpos, Evangelos, et al.
Publicado: (2021)

P-148: Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, except for those under treatment with anti-BCMA agents
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

Differential Dose- and Tissue-Dependent Effects of foxo on Aging, Metabolic and Proteostatic Pathways
por: Manola, Maria S., et al.
Publicado: (2021)

Smoking during pregnancy and gestational diabetes mellitus: a systematic review and meta-analysis
por: Athanasiadou, Kleoniki I., et al.
Publicado: (2023)

Boosting autophagy in anti-tumor proteasome inhibition-mediated cardiotoxicity
por: Papanagnou, Eleni-Dimitra, et al.
Publicado: (2023)

Nutrigenomics as a tool to study the impact of diet on aging and age-related diseases: the Drosophila approach
por: Evangelakou, Zoi, et al.
Publicado: (2019)

Screening and management of major endocrinopathies during pregnancy: an update
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Plasma Metabolomic Alterations Induced by COVID-19 Vaccination Reveal Putative Biomarkers Reflecting the Immune Response
por: Dagla, Ioanna, et al.
Publicado: (2022)

Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis
por: Trougakos, Ioannis P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l6qc2p44ucbl4ur1nuofnqm26u